What question did this study set out to answer?

January 14, 2026Open Forum Infectious Diseases0 citationsOpen Access

P-1168. Pharmacokinetics, Safety, and Tolerability of Funobactam in Combination with Imipenem/Cilastatin in Subjects with Various Degrees of Renal Function

JLJianguo LiConcord Consortium QSQifeng ShiConcord Consortium JFJing FengConcord Consortium

Key Points

This research aims to evaluate the pharmacokinetics, safety, and tolerability of funobactam in combination with imipenem/cilastatin in patients with different degrees of renal function.
Evaluated various renal function cohorts based on eGFR measurements.
Collected blood and urine samples for drug concentration analysis via LC-MS/MS.
Monitored adverse events, ECGs, and vital signs for safety assessment.
Clearances of funobactam decreased progressively with increasing renal impairment.
Mean AUC0-∞ of funobactam increased in subjects with renal insufficiency.
Administration of funobactam with imipenem and cilastatin was well tolerated.

Abstract

Abstract Background Funobactam (formerly XNW4107) is a novel non-β-lactam diazabicyclooctane β-lactamase inhibitor with potent and selective direct activity against Ambler classes of A, C, D β–lactamases. This study evaluated pharmacokinetics (PK), safety, and tolerability of a single intravenous (IV) dose of imipenem 500 mg/ cilastatin 500 mg in combination with funobactam 250 mg or imipenem 200 mg/ cilastatin 200 mg in combination with funobactam 100 mg in subjects with various degrees of renal function. Methods Thirty-nine subjects were enrolled into 5 study cohorts with normal renal function with an estimated glomerular filtration rate (eGFR) ≥ 90 mL/min/1.73m2 (Cohort 1), mild renal impairment with eGFR ≥ 60 to 90 mL/min/1.73m2 (Cohort 2), moderate renal impairment with eGFR ≥ 30 to 60 mL/min/1.73m2 (Cohort 3), severe renal impairment with eGFR ≥ 15 to 30 mL/min/1.73m2 (Cohort 4) and subjects receiving hemodialysis (Cohort 5). Blood and urine samples were collected to determine funobactam, imipenem and cilastatin concentrations by LC-MS/MS method. The safety and tolerability were assessed by monitoring adverse events, ECGs, vital sign measurements, physical examinations, and clinical laboratory data. Results The mean (SD) of PK parameters for funobactam are shown in the table below:PKParameter (units)Cohort 1 (N=8)Cohort 2 (N=8)Cohort 3 (N=8)Cohort 4 (N=7)Cohort 5 (N=8)Cmax (µg/mL)15.36 (2.72)16.7 (2.39)15.8 (2.45)6.89 (1.29)5.18 (0.97)AUC0-inf (µg*h/mL)46.7 (7.73)61.6 (10.8)106 (26.1)67.6 (14.9)180 (34.9)CL (L/h)5.52 (1.20)4.18 (0.75)2.47 (0.57)1.55 (0.39)0.58 (0.11)VZ (L)22.9 (3.98)21.8 (4.54)20.5 (3.18)22.2 (3.44)21.1 (4.01)t1/2 (h)2.89 (0.11)3.62 (0.46)6.05 (1.77)10.2 (1.95)25.7 (4.15)CLr3.93 (1.12)3.34 (0.90)1.82 (0.68)0.94 (0.37)NA Conclusion Overall, the clearances of funobactam were progressively decreased with the increasing renal insufficiency for subjects with mild, moderate, severe renal impairment, and subjects receiving hemodialysis, and resulted in correspondingly progressive increase in AUC0-∞. Dose adjustment could likely be needed in subjects with renal impairment. Administration of funobactam in combination with imipenem and cilastatin was safe and well tolerated in subjects with normal and impaired renal function. Disclosures All Authors: No reported disclosures

Ask AI

Helpful

Bookmark

View Full Paper